IMTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immatics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.26 |
| 52 Week High | US$13.77 |
| 52 Week Low | US$3.30 |
| Beta | 0.85 |
| 1 Month Change | -16.63% |
| 3 Month Change | -20.37% |
| 1 Year Change | -58.48% |
| 3 Year Change | -48.30% |
| 5 Year Change | -59.81% |
| Change since IPO | -55.63% |
Recent News & Updates
Immatics N.V.: Trading Below Cash, But Not Without Reason
Mar 28Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price
Jan 12
Recent updates
Immatics N.V.: Trading Below Cash, But Not Without Reason
Mar 28Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price
Jan 12Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues
Sep 21Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans
Jul 12Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now
May 03We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Sep 26We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Jun 12Immatics launches $110M stock offering
Oct 10Cancer immunotherapy biotech Immatics up 18% on 4x normal volume
Jul 19Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation
Jan 29Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher
Dec 16Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Apr 01What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?
Jan 18Immatics reports Q3 results
Dec 02Immatics (IMTX) Investor Presentation - Slideshow
Nov 13Shareholder Returns
| IMTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.3% | 1.1% | -3.0% |
| 1Y | -58.5% | -8.5% | 4.6% |
Return vs Industry: IMTX underperformed the US Biotechs industry which returned -8.5% over the past year.
Return vs Market: IMTX underperformed the US Market which returned 4.6% over the past year.
Price Volatility
| IMTX volatility | |
|---|---|
| IMTX Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: IMTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMTX's weekly volatility (10%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 618 | Harpreet Singh | www.immatics.com |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
Immatics N.V. Fundamentals Summary
| IMTX fundamental statistics | |
|---|---|
| Market cap | US$499.57m |
| Earnings (TTM) | US$17.31m |
| Revenue (TTM) | US$177.25m |
29.9x
P/E Ratio2.9x
P/S RatioIs IMTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMTX income statement (TTM) | |
|---|---|
| Revenue | €155.84m |
| Cost of Revenue | €148.08m |
| Gross Profit | €7.76m |
| Other Expenses | -€7.46m |
| Earnings | €15.22m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 4.98% |
| Net Profit Margin | 9.77% |
| Debt/Equity Ratio | 0% |
How did IMTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 22:52 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Immatics N.V. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |